Proteomic Analysis of Signaling Network Regulation in Renal Cell Carcinomas with Differential Hypoxia-Inducible Factor-2α Expression

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Da Nagaprashantha, Lokeshlasanur ^a   Talamantes, Tatjana ^a   Singhal, Jyotsana ^a   Guo, Jia ^a   Vatsyayan, Rit ^a   Rauniyar, Navin ^a   Awasthi, Sanjay ^a   Singhal, Sharad S ^a   Prokai, Laszlo ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN; HYPOXIA INDUCIBLE FACTOR 2ALPHA; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL ENERGY; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; GENOTYPING TECHNIQUE; GLYCOLYSIS; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR DYNAMICS; OXIDATIVE STRESS; PROTEIN DEPLETION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; UPREGULATION; WILD TYPE;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; METABOLIC NETWORKS AND PATHWAYS; MUTATION; PROTEOME; PROTEOMICS; SIGNAL TRANSDUCTION; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84881087738     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071654     Document Type: Article

References (38)

1. Pfaffenroth EC, Linehan WM, (2008) Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. Expert Opin Biol Ther 8: 779-790.
2. Arjumand W, Sultana S, (2012) Role of VHL gene mutation in human renal cell carcinoma. Tumor Biol 33: 9-16.
3. Kaelin WG Jr, (2008) The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8: 865-873.
4. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275.
5. Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr, (2003) Inhibition of HIF2α is sufficient to suppress VHL-defective tumor growth. PLoS Biol 1: E83.
6. Shinojima T, Oya M, Takayanagi A, Mizuno R, Shimizu N, et al. (2007) Renal cancer cells lacking hypoxia inducible factor (HIF)-1α expression maintain vascular endothelial growth factor expression through HIF2α. Carcinogenesis 28: 529-536.
7. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC, (2003) Differential roles of hypoxia-inducible factor 1alpha (HIF1α) and HIF2α in hypoxic gene regulation. Mol Cell Biol 23: 9361-9374.
8. Lai Y, Qiao M, Song M, Weintraub ST, Shiio Y, (2011) Quantitative proteomics identifies the Myb-binding protein p160 as a novel target of the von Hippel-Lindau tumor suppressor. PLoS One 6: e16975.
9. Lai Y, Song M, Hakala K, Weintraub ST, Shiio Y, (2011) Proteomic dissection of the von Hippel-Lindau (VHL) interactome. J Proteome Res 10: 5175-5182.
10. Choi JW, Park SC, Kang GH, Liu JO, Youn HD, (2004) Nur77 activated by hypoxia-inducible factor-1alpha overproduces proopiomelanocortin in von Hippel-Lindau-mutated renal cell carcinoma. Cancer Res 64: 35-39.
11. Singhal SS, Sehrawat A, Sahu M, Singhal P, Vatsyayan R, et al. (2010) RLIP76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int J Cancer 126: 1327-1338.
12. Nagaprashantha DL, Singhal J, Vatsyayan R, Lelsani P, Singhal SS, et al. (2010) Proteomic analysis of drug metabolizing networks in renal cell carcinomas with differential drug sensitivity and VHL expression. J Clin Oncol 28suppl; abstr e13137.
13. McDonald WH, Yates JR 3rd, (2002) Shotgun proteomics and biomarker discovery. Dis Markers 18: 99-105.
14. Wu CC, MacCoss MJ, Howell KE, Yates JR 3rd, (2003) A method for the comprehensive proteomic analysis of membrane proteins. Nat Biotechnol 21: 532-538.
15. Washburn MP, Ulaszek R, Deciu C, Schieltz DM, Yates JR 3rd, (2002) Analysis of quantitative proteomic data generated via multidimensional protein identification technology. Anal Chem 74: 1650-1657.
16. Wang M, You J, Bemis KG, Tegeler TJ, Brown DP, (2008) Label-free mass spectrometry-based protein quantification technologies in proteomic analysis. Brief Funct Genom Proteom 7: 329-339.
17. Stevens SM Jr, Duncan RS, Koulen P, Prokai L, (2008) Proteomic analysis of mouse brain microsomes: identification and bioinformatics characterization of endoplasmic reticulum proteins in the mammalian central nervous system. J Proteome Res 7: 1046-1054.
18. Prokai L, Stevens SM Jr, Rauniyar N, Nguyen V, (2009) Rapid label-free identification of estrogen-induced differential protein expression in vivo from mouse brain and uterine tissue. J Proteome Res 8: 3862-3871.
19. Wilm M, (2009) Quantitative proteomics in biological research. Proteomics 9: 4590-4605.
20. Keller A, Nesvizhskii AI, Kolker E, Aebersold R, (2002) Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 74: 5383-5392.21.
21. Nesvizhskii AI, Keller A, Kolker E, Aebersold R, (2003) A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 75: 4646-4658.
22. Vizcaino JA, Cote RG, Csordas A, Dianes JA, Fabregat A, et al. (2013) The proteomics identifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res 41: D1063-D1069.
23. Togashi A, Katagiri T, Ashida S, Fujioka T, Maruyama O, et al. (2005) Hypoxia-inducible protein 2 (HIG2), a novel diagnostic marker for renal cell carcinoma and potential target for molecular therapy. Cancer Res 65: 4817-4826.
24. Siemeister G, Weindel K, Mohrs K, Barleon B, Martiny-Baron G, et al. (1996) Reversion of deregulated expression of VEGF in human renal cell carcinoma cells by von Hippel- Lindau tumour suppressor protein. Cancer Res 56: 2299-2301.
25. Soussy T, (2011) TP53 mutations in human cancer: database reassessment and prospects for the next decade. Adv Cancer Res 110: 107-139.
26. Arlt VM, Zuo J, Trenz K, Roufosse CA, Lord GM, et al. (2011) Gene expression changes induced by the human carcinogen aristolochic acid I in renal and hepatic tissue of mice. Int J Cancer 128: 21-32.
27. Keith B, Johnson RS, Simon MC, (2012) HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12: 9-22.
28. Kroemer G, Pouyssegur J, (2008) Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13: 472-482.
29. Warburg O, (1956) On the origin of cancer cells. Science 123: 309-314.
30. Perroud B, Lee J, Valkova N, Dhirapong A, Lin PY, et al. (2006) Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer 5: 64.
31. Unwin RD, Craven RA, Harnden P, Hanrahan S, Totty N, et al. (2003) Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics 3: 1620-1632.
32. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB, (2008) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7: 11-20.
33. Mnatsakanyan N, Kemboi SK, Salas J, Weber JJ, (2011) The beta subunit loop that couples catalysis and rotation in ATP synthase has a critical length. Biol Chem 34: 29788-2996.
34. Tennant DA, Durán RV, Gottlieb E. (2010) Targeting metabolic transformation for cancer therapy. Nature Reviews Cancer 10: 267-277.
35. Schumacker PT, (2006) Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 10: 175-176.
36. Chiou JF, Tai CJ, Wang YH, Liu TZ, Jen YM, et al. (2009) Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism. Cancer Biol Ther 8: 1904-1913.
37. Ciocca DR, Calderwood SK, (2005) Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10: 86-103.
38. Singh MP, Reddy MM, Mathur N, Saxena DK, Chowdhuri DK, (2009) Induction of hsp70, hsp60, hsp83 and hsp26 and oxidative stress markers in benzene, toluene and xylene exposed Drosophila melanogaster: role of ROS generation. Toxicol Appl Pharmacol 235: 226-243.